Clinical trials: Hematologic
Sickle Cell Disease
HLA Haploidentical Bone Marrow Transplant in Patients With Severe Sickle Cell Disease
multicentric interventional biomedical research phase II, prospective, non-randomized evaluating a haploidentical marrow transplants after reduced-intensity conditioning and prevention of GvHD based on cyclophosphamide…
- Trial name
- DREPHAPLO (NCT03240731)
- Testing
- bone marrow transplant
- Where
- 7 sites in France
- Volunteers
- 25 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Chronic Lymphocytic Leukemia (CLL)
A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).
The purpose of this open-label, single-arm study was to evaluate the impact of venetoclax on the quality of life of participants including those with with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL; a type of…
- Trial name
- VENICE II (NCT02980731)
- Testing
- Venetoclax
- Where
- 33 sites in Argentina, Australia and 8 more
- Volunteers
- 210 people
- Sponsor
- AbbVie
Multiple Myeloma (MM), Cancer
A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma
This first-in-human study will evaluate the safety and tolerability of ABBV-467 in adult participants with relapsed/refractory multiple myeloma (MM).
- Trial name
- NCT04178902
- Testing
- ABBV-467
- Where
- 24 sites in United States, Australia and 5 more
- Volunteers
- 8 people
- Sponsor
- AbbVie
Multiple Myeloma
Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)
This is a phase I/II, single arm, open label, two-part study that will assess safety, tolerability and clinical activity of GSK2857916 given in combination with a programmed cell death-1 (PD-1) inhibitor pembrolizumab in subjects…
- Trial name
- DREAMM 4 (NCT03848845)
- Testing
- belantamab mafodotin, Pembrolizumab
- Where
- 12 sites in United States, Canada and 2 more
- Volunteers
- 41 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma, Plasmocytoma
Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma
Patients with stage-I multiple myeloma are treated with a vaccine made from their own immune cells (dendritic cells) and their own myeloma protein. Vaccinations are given on 5 occasions every 4 weeks.
- Trial name
- NCT00988312
- Testing
- autologous idiotype-protein pulsed dendritic cells
- Where
- Germany
- Volunteers
- 9 people
- Sponsor
- University Hospital Carl Gustav Carus
Brain and Central Nervous System Tumors, Breast Cancer
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00019019
- Testing
- carboxyamidotriazole, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Heart Failure, High Blood Pressure
BVA-200 vs BVA-100 Validation Study
The proposed study is a prospective, observational, investigator and patient blinded study comparing the results of blood volume measurement using the FDA-cleared Daxor BVA-100 device to the Daxor BVA-200 device.
- Conditions
- Heart Failure, High Blood Pressure, High Cholesterol, Anemia
- Trial name
- NCT06227819
- Testing
- BVA-200
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Daxor Corporation
Leukemia, Chronic Myeloid
Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment
The aim of this study was to evaluate the real-world treatment patterns, healthcare resource use and costs among patients newly diagnosed with CML who were treated with tyrosine kinase inhibitors (TKIs) in first- and second-line…
- Trial name
- NCT07188428
- Where
- United States
- Volunteers
- 2,298 people
- Sponsor
- Novartis Pharmaceuticals
Relapsed or Refractory Acute Myeloid Leukemia
Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
To evaluate the efficacy and safety of venetoclax, chidamide, and chiglitazar sodium (VCC) in patients with relapsed or refractory acute myeloid leukemia (R/R AML).
- Trial name
- NCT07783100
- Testing
- venetoclax, chidamide, and chiglitazar sodium (VCC)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Hematologic Neoplasms
Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers
This study will investigate the safety and effectiveness of a modified stem cell transplant procedure for treating cancers of the blood and immune system.
- Trial name
- NCT00051311
- Testing
- Stem cell transplantation, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute (NCI)
Sickle Cell Anemia
Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
Hydroxyurea (HU) is approved by the United States Food and Drug Administration (FDA) to treat adults with sickle cell anemia. Hydroxyurea has also been tested and used with children with sickle cell anemia.
- Trial name
- HU (NCT01506544)
- Testing
- Hydroxyurea
- Where
- 6 sites in United States
- Volunteers
- 39 people
- Sponsor
- Children's Mercy Hospital Kansas City
Solid and Hematological Malignancies, Autoimmune Diseases
Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies
The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-363, KITE-753, KITE-197, anitocabtagene…
- Trial name
- NCT05041309
- Testing
- Axicabtagene Ciloleucel, Brexucabtagene Autoleucel, Anitocabtagene autleucel
- Where
- 91 sites in United States, Australia and 12 more
- Volunteers
- 1,500 people
- Sponsor
- Kite, A Gilead Company
B-Cell ALL, B-Cell Acute Lymphoblastic Leukaemia
A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab
The goal of this observational study is to establish a clear vaccination protocol for pediatric patients (less than 21 years old) who have received treatment for B-cell Acute Lymphoblastic Leukemia/Lymphoma.
- Conditions
- B-Cell ALL, B-Cell Acute Lymphoblastic Leukaemia, B-Cell Lymphoblastic Leukemia, B-Cell Lymphoblastic Leukemia/Lymphoma
- Trial name
- BOOSTER (NCT07422337)
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Arkansas Children's Hospital Research Institute
Leukemia
Hormone Therapy Plus Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
RATIONALE: Hormone therapy may stop the growth of cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00003437
- Testing
- asparaginase, cyclophosphamide, cytarabine
- Where
- United Kingdom
- Volunteers
- 1,800 people
- Sponsor
- Medical Research Council
Multiple Myeloma
An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments
Belantamab mafodotin (GSK2857916) is a first in class, antibody dependent cellular cytotoxicity (ADCC) enhanced, humanized immunoglobulin G1 (IgG1) antibody-drug conjugate (ADC) which binds specifically to B cell maturation…
- Trial name
- NCT03828292
- Testing
- Belantamab mafodotin, Bortezomib, Dexamethasone
- Where
- 4 sites in Japan
- Volunteers
- 15 people
- Sponsor
- GlaxoSmithKline
Anemia
Periconceptional Iron Supplementation in Rural Bangladesh
The investigators hypothesize that periconceptional iron supplementation to married, nulliparous women in rural Bangladesh will significantly reduce anemia and improve hemoglobin concentrations before and during pregnancy.
- Trial name
- NCT00953134
- Testing
- Ferrous fumarate (iron), folic acid
- Where
- Bangladesh
- Volunteers
- 273 people, healthy volunteers welcome
- Sponsor
- The Hospital for Sick Children
Hepatitis C
Ribavirin Bioavailability After Telaprevir Exposure
Anemia is more frequent in patients receiving telaprevir with pegylated-interferon/ribavirin than in those receiving pegylated-interferon/ribavirin alone.
- Trial name
- NCT02881034
- Testing
- Triple therapy
- Where
- France
- Volunteers
- 37 people
- Sponsor
- Hospices Civils de Lyon
Blood Coagulation Disorders, Hemorrhage
Transfusion of Fresh Frozen Plasma in Non-bleeding Intensive Care Unit (ICU) Patients
With the aim to restrict inappropriate fresh frozen plasma (FFP) transfusions to critically ill patients, a randomized clinical trial will be conducted in a subgroup of intensive care (ICU) patients undergoing an invasive…
- Trial name
- TOPIC (NCT01143909)
- Testing
- omitting FFP transfusion before an intervention
- Where
- 4 sites in Netherlands
- Volunteers
- 81 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Relapsed/Refractory, Multiple Myeloma
A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)
The purpose of this study is to assess the safety and tolerability, maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of TAK-079 monotherapy and when combined with a backbone regimen of pomalidomide and dexamethasone…
- Trial name
- NCT03439280
- Testing
- Mezagitamab, Pomalidomide, Dexamethasone
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
VEXAS, VEXAS Syndrome
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
This trial is to assess the effectiveness and safety of pacritinib in patients with VEXAS (i.e., Vacuoles in myeloid progenitors, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory manifestations, and somatic) syndrome.
- Trial name
- NCT06782373
- Testing
- Pacritinib
- Where
- 39 sites in United States, Canada and 6 more
- Volunteers
- 156 people
- Sponsor
- Swedish Orphan Biovitrum
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.